Novelos Therapeutics, Inc. (NVLT)
We are a biopharmaceutical company, established in 1996, commercializing oxidized glutathione-based compounds for the treatment of cancer and hepatitis.
NOV-002, our lead compound currently in Phase 3 development for non-small cell lung cancer (NSCLC), acts together with chemotherapy as a chemoprotectant and an immunomodulator. In May 2006, we finalized a Special Protocol Assessment (SPA) with the FDA for a single pivotal Phase 3 trial in advanced NSCLC in combination with first-line chemotherapy, and received Fast Track designation in August 2006. The primary endpoint of this trial is improvement in median overall survival. Patient enrollment commenced in November 2006 and is ongoing. NOV-002 is also in Phase 2 development for chemotherapy-resistant ovarian cancer and early-stage breast cancer and, in addition, is being developed for treatment of acute radiation injury.
| ||||
Total Income, Quarterly
Profit margin
Net income
Revenue / Net income
Short Term
Long Term
Accounts payable| 31 Dec, 69 | 31 Dec, 69 | 31 Dec, 69 | 31 Dec, 69 |
|---|---|---|---|
| 698000 | 250000 | 442000 | 478000 |
Chart
Short current long term debt| 31 Dec, 69 | 31 Dec, 69 | 31 Dec, 69 | 31 Dec, 69 |
|---|---|---|---|
| 207000 | 163000 | 80000 | 26000 |
Chart
Cash and cash equivalents| 31 Dec, 69 | 31 Dec, 69 | 31 Dec, 69 | 31 Dec, 69 |
|---|---|---|---|
| 1229000 | 1031000 | 1646000 | 5561000 |
Chart
Other current assets| 31 Dec, 69 | 31 Dec, 69 | 31 Dec, 69 | 31 Dec, 69 |
|---|---|---|---|
| 51000 | 57000 | 463000 | 255000 |
Chart
Long term debt| 31 Dec, 69 | 31 Dec, 69 | 31 Dec, 69 | 31 Dec, 69 |
|---|---|---|---|
| 3648000 | - | 455000 | 454000 |
Chart
Deferred long term liability charges| 31 Dec, 69 | 31 Dec, 69 | 31 Dec, 69 | 31 Dec, 69 |
|---|---|---|---|
| 115000 | 358000 | 121000 | 124000 |
Chart
Property plant and equipment| 31 Dec, 69 | 31 Dec, 69 | 31 Dec, 69 | 31 Dec, 69 |
|---|---|---|---|
| 3510000 | 7000 | 3184000 | 3045000 |
Chart
Other assets| 31 Dec, 69 | 31 Dec, 69 | 31 Dec, 69 | 31 Dec, 69 |
|---|---|---|---|
| 12000 | 15000 | 27000 | 27000 |
Chart
Short Term
Long Term
To see the headquarters in Google Street View &trade, drag this yellow guy: 
over to the red pointer: 
Contact Information:
| Business Address: | - |
| Mailing Address: | ONE GATEWAY CENTER, SUITE 504 NEWTON MA 02458 Business Address ONE GATEWAY CENTER, SUITE 504 NEWTON MA 02458 617-244-1616 NOVELOS THERAPEUTICS, INC. |
| Phone: | 617-244-1616 |
| Fax: | 617-964-6331 |
| Website: | http://www.novelos.com |
Company Details:
| Symbol: | NVLT |
| SIC: | - |
| State location: | MA |
| Sector: | - |
| State of Inc: | DE |
| Employees: | 8 |
| Type: | OTCBB |
Key executives:
| Name | Age | Position |
|---|---|---|
| Christopher J. Pazoles Ph.D | 61 | VP of R&D |
| George R. Vaughn CPA | 58 | Chief Financial Officer and Chief Accounting Officer |
| Harry S. Palmin | 41 | Chief Exec. Officer, Pres |
| Kristin Schuhwerk | - | Director of Operations |
| Simyon Palmin | 67 | Founder, Chairman of Russian Relations |
Novelos Therapeutics, Inc. (OTC:NVLT) The Positive Message Gets Dramatic... Dec 10, 2010
It looks like the real sell-off of Novelos Therapeutics, Inc. (OTC:NVLT) shares happened just yesterday afternoon. The initial joy from the at first sight positive message of the company's latest press release expired by the middle of the trading session and the share price dropped to a new yearly low.read more
| Post # | Subject | Re | Name | Date |
|---|---|---|---|---|
| 1 | This week I bought more shares cos they... | 0 | passive aggressive | January 23, 2008, 07:01AM |
| 2 | Here on this message board we are inviting... | 0 | Guest | January 23, 2008, 07:01AM |